Tarsier Pharma
IPOChanging Lives by Saving Sight
Public · $2.6M raised
- Website
- tarsierpharma.com
- Total Funding
- $2.6M
- Last Round
- $1.6M SAFEJul 2022
- Rounds
- 3
- Type
- Public
About
Tarsier Pharma is a late clinical-stage company developing bio-inspired treatments for autoimmune and inflammatory ocular diseases. Its patented Dazdotuftide platform uses a proprietary molecule intended to re-engineer immune-system activity and control inflammatory disease. The pipeline includes eye-drop and intravitreal-injection routes, with TRS01 in clinical development for non-infectious anterior uveitis, including uveitic glaucoma, and a broader focus on protecting patients from vision loss and blindness.
Summary
Tarsier Pharma is a Biotech company. It has raised $2.6M in total across 3 rounds, most recently a $1.6M SAFE round in Jul 2022.
Funding History
Jul 2026
Sign up to see all 4 rounds
SAFE through IPO — per-round amounts, valuations, and who invested in each round.
Similar Companies
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Specialty pharmaceutical company focused on addressing therapeutic needs in the fields of psychia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/tarsier-pharma"><img src="https://indexed.vc/api/badge/company/tarsier-pharma" alt="Tarsier Pharma on Indexed.vc" width="260" height="76" /></a>